The fecal microbiota as a biomarker for disease activity in Crohn's disease

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Tedjo, Danyta I ^a   Smolinska, Agnieszka ^a   Savelkoul, Paul H ^a   Masclee, Ad A ^a   Van Schooten, Frederik J ^a   Pierik, Marieke J ^a   Penders, John ^a   Jonkers, Daisy M A E ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; CROHN DISEASE; FECES; FEMALE; HUMAN; MALE; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; CROHN DISEASE; FECES; FEMALE; HUMANS; MALE; MICROBIOTA; MIDDLE AGED; YOUNG ADULT;

EID: 84991644072     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep35216     Document Type: Article

References (60)

1. Hilmi, I. et al. A First Study on the Incidence and Prevalence of IBD in Malaysia-Results From the Kinta Valley IBD Epidemiology Study. J. Crohns. Colitis 9, 404-409 (2015).
2. Molodecky, N. A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46-54.e42; quiz e30 (2012).
3. Baumgart, D. C. and Sandborn, W. J. Crohns disease. Lancet 380, 1590-1605 (2012).
4. Stallmach, A., Hagel, S. and Bruns, T. Adverse effects of biologics used for treating IBD. Best Pract. Res. Clin. Gastroenterol. 24, 167-182 (2010).
5. Rogler, G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract. Res. Clin. Gastroenterol. 24, 157-165 (2010).
6. Burisch, J., Jess, T., Martinato, M. and Lakatos, P. L. The burden of inflammatory bowel disease in Europe. J. Crohns. Colitis 7, 322-337 (2013).
7. Palmer, K. R. Complications of gastrointestinal endoscopy. Gut 56, 456-457 (2007).
8. Falvey, J. D. et al. Disease Activity Assessment in IBD: Clinical Indices and Biomarkers Fail to Predict Endoscopic Remission. Inflamm. Bowel Dis. 21, 824-831 (2015).
9. Vermeire, S., Van Assche, G. and Rutgeerts, P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55, 426-431 (2006).
10. af Björkesten, C.-G. et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti- TNF-treated luminal Crohns disease. Scand. J. Gastroenterol. 47, 528-537 (2012).
11. Manichanh, C., Borruel, N., Casellas, F. and Guarner, F. The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol. 9, 599-608 (2012).
12. Matsuoka, K. and Kanai, T. The gut microbiota and inflammatory bowel disease. Semin. Immunopathol. 37, 47-55 (2015).
13. Wright, E. K. et al. Recent advances in characterizing the gastrointestinal microbiome in Crohns disease: a systematic review. Inflamm. Bowel Dis. 21, 1219-1228 (2015).
14. De Cruz, P. et al. Association between specific mucosa-associated microbiota in Crohns disease at the time of resection and subsequent disease recurrence: a pilot study. J. Gastroenterol. Hepatol. 30, 268-278 (2015).
15. Manichanh, C. et al. Reduced diversity of faecal microbiota in Crohns disease revealed by a metagenomic approach. Gut 55, 205-211 (2006).
16. Scanlan, P. D., Shanahan, F., OMahony, C. and Marchesi, J. R. Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohns disease. J. Clin. Microbiol. 44, 3980-3988 (2006).
17. Andoh, A. et al. Faecal microbiota profile of Crohns disease determined by terminal restriction fragment length polymorphism analysis. Aliment. Pharmacol. Ther. 29, 75-82 (2009).
18. Sokol, H. et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis. 15, 1183-1189 (2009).
19. Takaishi, H. et al. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int. J. Med. Microbiol. 298, 463-472 (2008).
20. Verma, R., Verma, A. K., Ahuja, V. and Paul, J. Real-time analysis of mucosal flora in patients with inflammatory bowel disease in India. J. Clin. Microbiol. 48, 4279-4282 (2010).
21. Andoh, A. et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohns disease using terminal restriction fragment length polymorphism analysis. J. Gastroenterol. 46, 479-486 (2011).
22. Andoh, A. et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohns disease. J. Gastroenterol. 47, 1298-1307 (2012).
23. Wang, W. et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J. Clin. Microbiol. 52, 398-406 (2014).
24. Wills, E. S. et al. Fecal microbial composition of ulcerative colitis and Crohns disease patients in remission and subsequent exacerbation. PLoS One 9, e90981 (2014).
25. Seksik, P. et al. Alterations of the dominant faecal bacterial groups in patients with Crohns disease of the colon. Gut 52, 237-242 (2003).
26. Basset, C., Holton, J., Bazeos, A., Vaira, D. and Bloom, S. Are Helicobacter species and enterotoxigenic Bacteroides fragilis involved in inflammatory bowel disease? Dig. Dis. Sci. 49, 1425-1432 (2004).
27. Su, J. W., Ma, J. J. and Zhang, H. J. Use of antibiotics in patients with Crohns disease: a systematic review and meta-analysis. J. Dig. Dis. 16, 58-66 (2015).
28. Papa, E. et al. Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS One 7, e39242 (2012).
29. Gevers, D. et al. The treatment-naive microbiome in new-onset Crohns disease. Cell Host Microbe 15, 382-392 (2014).
30. Gophna, U., Sommerfeld, K., Gophna, S., Doolittle, W. F. and Veldhuyzen van Zanten, S. J. O. Differences between tissue-associated intestinal microfloras of patients with Crohns disease and ulcerative colitis. J. Clin. Microbiol. 44, 4136-4141 (2006).
31. Hansen, R. et al. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohns but not in ulcerative colitis. Am. J. Gastroenterol. 107, 1913-1922 (2012).
32. Van Assche, G. et al. The second European evidence-based Consensus on the diagnosis and management of Crohns disease: Definitions and diagnosis. J. Crohns. Colitis 4, 7-27 (2010).
33. van den Heuvel, T. R. et al. Cohort Profile: The Inflammatory Bowel Disease South Limburg Cohort (IBDSL). Int. J. Epidemiol, doi: 10.1093/ije/dyv088 (2015).
34. Bodelier, A. G. L. et al. Volatile Organic Compounds in Exhaled Air as Novel Marker for Disease Activity in Crohns Disease: A Metabolomic Approach. Inflamm. Bowel Dis. 21, 1776-1785 (2015).
35. DHaens, G. et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm. Bowel Dis. 18, 2218-2224 (2012).
36. Burbidge, J. B., Magee, L. and Robb, A. L. Alternative Transformations to Handle Extreme Values of the Dependent Variable. J. Am. Stat. Assoc. 83, 123 (1988).
37. Williamson, D. F., Parker, R. A. and Kendrick, J. S. The box plot: a simple visual method to interpret data. Ann. Intern. Med. 110, 916-921 (1989).
38. Engel, J. et al. Regularized MANOVA (rMANOVA) in untargeted metabolomics. Anal. Chim. Acta 899, 1-12 (2015).
39. Seksik, P. et al. Alterations of the dominant faecal bacterial groups in patients with Crohns disease of the colon. Gut 52, 237-242 (2003).
40. Kolho, K.-L. et al. Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation. Am. J. Gastroenterol. 110, 921-930 (2015).
41. Knights, D., Costello, E. K. and Knight, R. Supervised classification of human microbiota. FEMS Microbiol. Rev. 35, 343-359 (2011).
42. David, B. et al. Anti-TNF treatment with adalimumab induces changes in the microbiota of Crohns disease. J. Crohns. Colitis jjv119 doi: 10.1093/ecco-jcc/jjv119 (2015).
43. Andrews, C. N. et al. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 34, 374-383 (2011).
44. Westerhuis, J. A., van Velzen, E. J. J., Hoefsloot, H. C. J. and Smilde, A. K. Multivariate paired data analysis: multilevel PLSDA versus OPLSDA. Metabolomics 6, 119-128 (2010).
45. Karpievitch, Y. V., Hill, E. G., Leclerc, A. P., Dabney, A. R. and Almeida, J. S. An introspective comparison of random forest-based classifiers for the analysis of cluster-correlated data by way of RF+ + . PLoS One 4, e7087 (2009).
46. Adler, W., Potapov, S. and Lausen, B. Classification of repeated measurements data using tree-based ensemble methods. Comput. Stat. 26, 355-369 (2011).
47. Kumari, R., Ahuja, V. and Paul, J. Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India. World J. Gastroenterol. 19, 3404-3414 (2013).
48. Dörffel, Y., Swidsinski, A., Loening-Baucke, V., Wiedenmann, B. and Pavel, M. Common biostructure of the colonic microbiota in neuroendocrine tumors and Crohns disease and the effect of therapy. Inflamm. Bowel Dis. 18, 1663-1671 (2012).
49. Machiels, K. et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63, 1275-1283 (2014).
50. Swidsinski, A., Loening-Baucke, V., Vaneechoutte, M. and Doerffel, Y. Active Crohns disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm. Bowel Dis. 14, 147-161 (2008).
51. Varela, E. et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment. Pharmacol. Ther. 38, 151-161 (2013).
52. Vermeiren, J. et al. Decreased colonization of fecal Clostridium coccoides/Eubacterium rectale species from ulcerative colitis patients in an in vitro dynamic gut model with mucin environment. FEMS Microbiol. Ecol. 79, 685-696 (2012).
53. Wang, W. et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J. Clin. Microbiol. 52, 398-406 (2014).
54. Willing, B. et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohns disease. Inflamm. Bowel Dis. 15, 653-660 (2009).
55. Andoh, A. et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohns disease. J. Gastroenterol. 47, 1298-1307 (2012).
56. Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA 105, 16731-16736 (2008).
57. Walker, A. W. et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 11, 7 (2011).
58. Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA 105, 16731-16736 (2008).
59. Prindiville, T. P. et al. Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease. Emerg. Infect. Dis. 6, 171-174 (2000).
60. Wells, C. L. et al. Bacteroides fragilis enterotoxin modulates epithelial permeability and bacterial internalization by HT-29 enterocytes. Gastroenterology 110, 1429-1437 (1996).